Cargando…

Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion

PURPOSE: To identify the incidence of endophthalmitis and visual outcomes in eyes with Boston type 1 keratoprosthesis combined with pars plana vitrectomy and silicone oil insertion (KPro + PPV + SOI) as compared to eyes receiving Boston type 1 keratoprosthesis (KPro) alone. PATIENTS AND METHODS: Ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou Shousha, Mohamed, Eleiwa, Taher, Gibbons, Allister, Smith, Christopher, Edelstein, Sean, Kontadakis, George, Schmitz, Zachary, Abernathy, Joshua, Chod, Ross, Bodnar, Zachary, McDaniel, Kelvin, Bentivegna, Rocio, Akduman, Levent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701324/
https://www.ncbi.nlm.nih.gov/pubmed/31467698
http://dx.doi.org/10.1155/2019/9648614
_version_ 1783445032110391296
author Abou Shousha, Mohamed
Eleiwa, Taher
Gibbons, Allister
Smith, Christopher
Edelstein, Sean
Kontadakis, George
Schmitz, Zachary
Abernathy, Joshua
Chod, Ross
Bodnar, Zachary
McDaniel, Kelvin
Bentivegna, Rocio
Akduman, Levent
author_facet Abou Shousha, Mohamed
Eleiwa, Taher
Gibbons, Allister
Smith, Christopher
Edelstein, Sean
Kontadakis, George
Schmitz, Zachary
Abernathy, Joshua
Chod, Ross
Bodnar, Zachary
McDaniel, Kelvin
Bentivegna, Rocio
Akduman, Levent
author_sort Abou Shousha, Mohamed
collection PubMed
description PURPOSE: To identify the incidence of endophthalmitis and visual outcomes in eyes with Boston type 1 keratoprosthesis combined with pars plana vitrectomy and silicone oil insertion (KPro + PPV + SOI) as compared to eyes receiving Boston type 1 keratoprosthesis (KPro) alone. PATIENTS AND METHODS: Retrospective chart review of 29 eyes of 27 patients with KPro having at least 12-month follow-up. Thirteen of these eyes had hypotony and/or retinal detachment in addition to corneal pathology and thus received KPro + PPV + SOI. Polymyxin-trimethoprim with a quinolone was used as chronic topical antibiotic prophylaxis in both groups after the first postoperative month. Outcome measures recorded at the 1-, 3-, 6-, 12-, and 24-month follow-up visits included best-corrected visual acuity (BCVA) and rates of postoperative complications. RESULTS: All the patients had completed 24-month follow-up except one case in the KPro group who lost to follow-up after 12-month visit. In the KPro + PPV + SOI group, no eyes had developed endophthalmitis by the 24-month follow-up visit versus 5 eyes of 5 patients in the uncombined KPro group (P=0.048). The 2-year cumulative endophthalmitis incidence was 31.2% in the KPro group versus zero in the KPro + PPV + SOI group (P=0.030). Four of these 5 eyes had vitreous taps with positive cultures; 2 were positive with Staphylococcus aureus, 1 with coagulase-negative staphylococci, and 1 with Streptococcus pneumoniae. Other complications included KPro extrusion (1 in each group), retinal detachment (2 in the KPro and 1 in the KPro + PPV + SOI group), newly developed glaucoma (2 in each group), and retroprosthetic membrane (9 in the KPro and 5 in the KPro + PPV + SOI group). The KPro group had better average preoperative BCVA compared to those of the KPro + PPV + SOI group (−2.29 ± 0.72 LogMAR, versus −2.95 ± 0.30 LogMAR; P=0.004). No statistically significant difference in BCVA was noted in subsequent follow-up visits. CONCLUSION: The addition of PPV and SOI to the KPro implantation in the eyes with corneal pathology, as well as hypotony and/or retinal detachment, is a safe and effective procedure for visual rehabilitation. Pars plana vitrectomy and silicone oil insertion may have a protective effect against the development of postoperative endophthalmitis in eyes receiving KPro.
format Online
Article
Text
id pubmed-6701324
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-67013242019-08-29 Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion Abou Shousha, Mohamed Eleiwa, Taher Gibbons, Allister Smith, Christopher Edelstein, Sean Kontadakis, George Schmitz, Zachary Abernathy, Joshua Chod, Ross Bodnar, Zachary McDaniel, Kelvin Bentivegna, Rocio Akduman, Levent J Ophthalmol Clinical Study PURPOSE: To identify the incidence of endophthalmitis and visual outcomes in eyes with Boston type 1 keratoprosthesis combined with pars plana vitrectomy and silicone oil insertion (KPro + PPV + SOI) as compared to eyes receiving Boston type 1 keratoprosthesis (KPro) alone. PATIENTS AND METHODS: Retrospective chart review of 29 eyes of 27 patients with KPro having at least 12-month follow-up. Thirteen of these eyes had hypotony and/or retinal detachment in addition to corneal pathology and thus received KPro + PPV + SOI. Polymyxin-trimethoprim with a quinolone was used as chronic topical antibiotic prophylaxis in both groups after the first postoperative month. Outcome measures recorded at the 1-, 3-, 6-, 12-, and 24-month follow-up visits included best-corrected visual acuity (BCVA) and rates of postoperative complications. RESULTS: All the patients had completed 24-month follow-up except one case in the KPro group who lost to follow-up after 12-month visit. In the KPro + PPV + SOI group, no eyes had developed endophthalmitis by the 24-month follow-up visit versus 5 eyes of 5 patients in the uncombined KPro group (P=0.048). The 2-year cumulative endophthalmitis incidence was 31.2% in the KPro group versus zero in the KPro + PPV + SOI group (P=0.030). Four of these 5 eyes had vitreous taps with positive cultures; 2 were positive with Staphylococcus aureus, 1 with coagulase-negative staphylococci, and 1 with Streptococcus pneumoniae. Other complications included KPro extrusion (1 in each group), retinal detachment (2 in the KPro and 1 in the KPro + PPV + SOI group), newly developed glaucoma (2 in each group), and retroprosthetic membrane (9 in the KPro and 5 in the KPro + PPV + SOI group). The KPro group had better average preoperative BCVA compared to those of the KPro + PPV + SOI group (−2.29 ± 0.72 LogMAR, versus −2.95 ± 0.30 LogMAR; P=0.004). No statistically significant difference in BCVA was noted in subsequent follow-up visits. CONCLUSION: The addition of PPV and SOI to the KPro implantation in the eyes with corneal pathology, as well as hypotony and/or retinal detachment, is a safe and effective procedure for visual rehabilitation. Pars plana vitrectomy and silicone oil insertion may have a protective effect against the development of postoperative endophthalmitis in eyes receiving KPro. Hindawi 2019-07-25 /pmc/articles/PMC6701324/ /pubmed/31467698 http://dx.doi.org/10.1155/2019/9648614 Text en Copyright © 2019 Mohamed Abou Shousha et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Abou Shousha, Mohamed
Eleiwa, Taher
Gibbons, Allister
Smith, Christopher
Edelstein, Sean
Kontadakis, George
Schmitz, Zachary
Abernathy, Joshua
Chod, Ross
Bodnar, Zachary
McDaniel, Kelvin
Bentivegna, Rocio
Akduman, Levent
Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion
title Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion
title_full Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion
title_fullStr Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion
title_full_unstemmed Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion
title_short Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion
title_sort risk of endophthalmitis in boston type 1 keratoprosthesis combined with vitrectomy and silicone oil insertion
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701324/
https://www.ncbi.nlm.nih.gov/pubmed/31467698
http://dx.doi.org/10.1155/2019/9648614
work_keys_str_mv AT aboushoushamohamed riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT eleiwataher riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT gibbonsallister riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT smithchristopher riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT edelsteinsean riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT kontadakisgeorge riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT schmitzzachary riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT abernathyjoshua riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT chodross riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT bodnarzachary riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT mcdanielkelvin riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT bentivegnarocio riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion
AT akdumanlevent riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion